---
title: "AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294417197.md"
description: "AtriCure Chief Scientific Officer Vinayak Doraiswamy sold 6,000 common shares on July 28, 2026, at $38.88 per share, totaling $233,280. Following this transaction, his direct holdings decreased to 86,511 shares. The information was published by AtriCure Inc. via EDGAR."
datetime: "2026-07-30T21:13:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294417197.md)
  - [en](https://longbridge.com/en/news/294417197.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294417197.md)
---

# AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares

-   AtriCure Chief Scientific Officer Vinayak Doraiswamy sold 6,000 common shares on July 28, 2026 at USD 38.88. \* Direct holdings fell to 86,511 shares following the sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001862458-26-000011), on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ATRC.US](https://longbridge.com/en/quote/ATRC.US.md)

## Related News & Research

- [Board Member At AtriCure Exercises Options Worth $491K](https://longbridge.com/en/news/294530665.md)
- [AtriCure to join Needham Virtual MedTech & Diagnostics investor conference](https://longbridge.com/en/news/293928171.md)
- [AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year](https://longbridge.com/en/news/293959967.md)
- [Atricure Still Faces Broad, Evolving Risks Despite No Material Changes in 2025 10-K Disclosures](https://longbridge.com/en/news/294017350.md)
- [AtriCure Q2 revenue beats estimates](https://longbridge.com/en/news/293661206.md)